Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Pharmaceutical Safety Assessment Market Poised To Hit $16.96 Billion By 2030 With A 8.5% CAGR
The pharmaceutical safety assessment market size has demonstrated strong growth in recent years. It is anticipated to expand from $11.32 billion in 2025 to $12.24 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. The expansion observed in prior periods can be attributed to factors such as the development of pharmaceutical research and development pipelines, increased regulatory oversight regarding drug safety, a rise in preclinical and clinical testing volumes, more widespread adoption of in-vitro safety assessment methodologies, and the increasing utilization of CRO-led safety studies.
The pharmaceutical safety assessment market is projected to experience robust expansion over the coming years. This market is forecast to reach $16.97 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast timeframe is primarily driven by an increased dependence on computational safety evaluations, the broadening scope of personalized medicine development, a growing need for quicker regulatory clearances, the escalating incorporation of AI into drug safety processes, and more stringent post-market surveillance mandates. Key developments expected within this period encompass the greater deployment of AI-powered toxicity prediction tools, an uptick in the acceptance of in-silico safety evaluation models, the expanding integration of real-time pharmacovigilance solutions, the proliferation of automated preclinical testing platforms, and a heightened emphasis on safety analytics that adhere to regulatory standards.
Get A Free Sample Report With In-Depth Market Insights:
Pharmaceutical Safety Assessment Market Industry Drivers: What’s Behind The Revenue Growth?
The future expansion of clinical trials is expected to propel the growth of the pharmaceutical safety assessment market. Clinical trials represent research investigations conducted in humans to evaluate the safety, effectiveness, and side effects of new medical treatments, drugs, or interventions. The rise in clinical trials is attributed to the increasing demand for novel and effective treatments, as researchers and healthcare providers aim to develop therapies that can better prevent, manage, or cure diseases. These trials support pharmaceutical safety assessment by systematically evaluating a drug’s effects on humans through carefully controlled studies, monitoring for adverse reactions, determining safe dosage ranges, and providing essential data that regulatory authorities use to ensure that medications are both effective and safe for public use. For instance, in September 2025, according to the National Library of Medicine (NLM), a US-based biomedical library, a total of 554,798 studies were registered on ClinicalTrials.gov as of September 26, 2025. Therefore, the expansion of clinical trials is driving the growth of the pharmaceutical safety assessment market.
Pharmaceutical Safety Assessment Market Breakdown By Product Type And Application
The pharmaceutical safety assessment market covered in this report is segmented –
1) By Type: In-Vitro Safety Assessment, In-Vivo Safety Assessment, Computational Safety Assessment
2) By Drug Type: Biological Drugs, Chemical Drugs
3) By Phase: Preclinical, Clinical (Phase I, II, III), Post-Market Surveillance (Phase IV)
4) By End User: Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, Academic And Research Institutions, Contract Research Organizations (CROs)
Subsegments:
1) By In-Vitro Safety Assessment: Cell-Based Assays, Organotypic Models, Tissue Culture Models, High-Throughput Screening
2) By In-Vivo Safety Assessment: Rodent Studies, Non-Rodent Studies, Toxicokinetic Studies, Carcinogenicity Studies
3) By Computational Safety Assessment: Quantitative Structure-Activity Relationship (QSAR) Modeling, Physiologically Based Pharmacokinetic (PBPK) Modeling, Toxicity Prediction Software, In Silico Simulation Studies
#Pharmaceutical Safety Assessment Market Growth Trends: What’s Shaping The Future Outlook?
Major companies in the pharmaceutical safety assessment market are concentrating on creating AI-driven decision support tools to enhance the precision and efficiency of toxicity prediction and safety profiling. An AI-powered decision support tool is a software system that uses artificial intelligence to process data and provide insights, thereby supporting quicker and more accurate decision-making. For instance, in April 2024, Charles River Laboratories, a US-based life sciences company, in partnership with Deciphex, an Ireland-based company that enhances diagnostic precision and speed through AI-driven quality assurance, launched the Patholytix Foresight platform. This AI-powered decision support tool is specifically designed to revolutionize toxicologic pathology within pharmaceutical safety assessment. The platform utilizes artificial intelligence to rapidly analyze intricate preclinical pathology data, helping to identify potential safety risks sooner and reducing the subjective element in results. It offers distinct features such as an AI algorithm for detecting tissue abnormalities, a cloud-based system for global collaboration, and a scalable design that minimizes slide review time while simultaneously improving data accuracy and consistency.
Pharmaceutical Safety Assessment Market Company Landscape And Competitive Strategy
Major companies operating in the pharmaceutical safety assessment market are IQVIA Holding Inc., LabCorp (formerly Covance), Thermo Fisher Scientific (PPD), Charles River Laboratories, ICON plc, Parexel International Corp., Syneos Health, Eurofins Scientific SE, Wuxi Biologics Inc., SGS SA, Medpace Holdings Inc., Fujifilm Wako (Fujifilm Corp.), Pharmaron Beijing Co. Ltd., Inotiv (incl. Envigo), Evotec (Cyprotex), Intertek Group, Altasciences Inc., Aragen Life Sciences Ltd., CTI Clinical Trial and Consulting Inc., ChemDiv Inc., Frontage Laboratories, Medicilon Inc., Biotoxtech Co. Ltd., BioIVT, Accelera Srl.
View The Full Pharmaceutical Safety Assessment Market Report:
Pharmaceutical Safety Assessment Market Largest Region By Revenue And Market Share
North America was the largest region in the pharmaceutical safety assessment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical safety assessment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
